Monitoring of interferon beta bioactivity in the multiple sclerosis

Abstract

Interferons beta (IFN-beta) are among the first-line agents for the treatment of multiple sclerosis (MS). MS patients on such therapies need to be monitored carefully for IFN-beta bioactivity, based on the measurement of IFN-beta neutralizing antibodies and myxovirus resistance protein A (MxA) mRNA levels.

An illustrative case report from clinical practice is presented.

Keywords

• interferon beta
• glatiramer acetate
• multiple sclerosis
• neutralizing antibodies
• Myxovirus resistance protein A